{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:33:11Z","timestamp":1791592391501,"version":"4.3.4"},"reference-count":137,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Government of India Department of Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jpet.2025.103735","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T03:36:14Z","timestamp":1759203374000},"page":"103735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unraveling synucleinopathies: Recent breakthroughs in Parkinson\u2019s disease therapy"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-3628","authenticated-orcid":false,"given":"Anjuman","family":"Nanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6171-1306","authenticated-orcid":false,"given":"Shivam Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-6162","authenticated-orcid":false,"given":"Rakesh Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jpet.2025.103735_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jpet.2025.103735_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jpet.2025.103735_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.986668","article-title":"Recent developments in nucleic acid-based therapies for Parkinson\u2019s disease: current status, clinical potential, and future strategies","volume":"13","author":"Pandey","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9996","key":"10.1016\/j.jpet.2025.103735_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","article-title":"The future of stem cell therapies for Parkinson disease","volume":"21","author":"Parmar","year":"2020","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103735_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis"},{"issue":"5999","key":"10.1016\/j.jpet.2025.103735_bib7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"issue":"49","key":"10.1016\/j.jpet.2025.103735_bib8","doi-asserted-by":"crossref","first-page":"11165","DOI":"10.1523\/JNEUROSCI.2559-04.2004","article-title":"Role of alpha-synuclein in presynaptic dopamine recruitment","volume":"24","author":"Yavich","year":"2004","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib9","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1038\/s41598-020-63412-x","article-title":"\u03b1-Synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory nucleus of the Parkinson\u2019s disease olfactory bulb","volume":"10","author":"Stevenson","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-023-00614-w","article-title":"Aggregate-prone brain regions in Parkinson\u2019s disease are rich in unique N-terminus \u03b1-synuclein conformers with high proteolysis susceptibility","volume":"10","author":"Wiseman","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jpet.2025.103735_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fneur.2019.00218","article-title":"Parkinson\u2019s disease and the environment","volume":"10","author":"Ball","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.jpet.2025.103735_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2020.00337","article-title":"Immunotherapies in Huntington\u2019s disease and \u03b1-synucleinopathies","volume":"11","author":"Fatoba","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"issue":"39","key":"10.1016\/j.jpet.2025.103735_bib15","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2023.140943","article-title":"Antibodies and \u03b1-synuclein: what to target against Parkinson\u2019s disease?","volume":"1872","author":"Otzen","year":"2024","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"s2","key":"10.1016\/j.jpet.2025.103735_bib17","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.3233\/JPD-191721","article-title":"Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis","volume":"9","author":"Borghammer","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mds.26481","article-title":"Development of passive immunotherapies for synucleinopathies","volume":"31","author":"Bergstr\u00f6m","year":"2016","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41531-021-00271-x","article-title":"Specific immune status in Parkinson\u2019s disease at different ages of onset","volume":"8","author":"Tian","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbadis.2008.09.001","article-title":"Intrabody and Parkinson\u2019s disease","volume":"1792","author":"Zhou","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib21","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s13346-020-00873-7","article-title":"Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review","volume":"11","author":"Gao","year":"2021","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"10.1016\/j.jpet.2025.103735_bib23","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.3390\/ijms22126517","article-title":"Alpha-synuclein as a prominent actor in the inflammatory synaptopathy of Parkinson\u2019s disease","volume":"22","author":"Cardinale","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103735_bib24","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.3390\/ijms24032477","article-title":"The interplay between \u03b1-synuclein and microglia in \u03b1-synucleinopathies","volume":"24","author":"Deyell","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103735_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JPD-150630","article-title":"Immunotherapy in Parkinson\u2019s disease: micromanaging alpha-synuclein aggregation","volume":"5","author":"George","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.jpet.2025.103735_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2018.02.011","article-title":"Interleukin-1\u03b2, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-\u03b1 levels in CSF and serum in relation to the clinical diversity of Parkinson\u2019s disease","volume":"327","author":"Karpenko","year":"2018","journal-title":"Cell Immunol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00213-023-06382-y","article-title":"L-theanine attenuates LPS-induced motor deficit in experimental rat model of Parkinson\u2019s disease: emphasis on mitochondrial activity, neuroinflammation, and neurotransmitters","volume":"240","author":"Kumar","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib28","first-page":"182","article-title":"Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease","volume":"119","author":"Brochard","year":"2009","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.jpet.2025.103735_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.parkreldis.2005.07.005","article-title":"Alterations of T-lymphocyte populations in Parkinson disease","volume":"11","author":"Baba","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jnc.12263","article-title":"IL-1\u03b2 and TNF-\u03b1 induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase","volume":"125","author":"Ye","year":"2013","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.jpet.2025.103735_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/glia.22437","article-title":"Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia","volume":"61","author":"Fellner","year":"2013","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib32","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1038\/s41467-021-25767-1","article-title":"Selective targeting of the TLR2\/MyD88\/NF-\u03baB pathway reduces \u03b1-synuclein spreading in vitro and in vivo","volume":"12","author":"Dutta","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jpet.2025.103735_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbi.2018.12.003","article-title":"TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson\u2019s diseases in vivo model","volume":"76","author":"Campolo","year":"2019","journal-title":"Brain Behav Immun"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib34","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.neurobiolaging.2015.03.015","article-title":"P2X7 receptor is critical in \u03b1-synuclein\u2013mediated microglial NADPH oxidase activation","volume":"36","author":"Jiang","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"15","key":"10.1016\/j.jpet.2025.103735_bib35","doi-asserted-by":"crossref","first-page":"E1926","DOI":"10.1073\/pnas.1417883112","article-title":"\u03b1-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpet.2025.103735_bib36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.redox.2017.11.010","article-title":"Integrin CD11b mediates \u03b1-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway","volume":"14","author":"Hou","year":"2018","journal-title":"Redox Biol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103735_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111401","article-title":"Interaction of RAGE with \u03b1-synuclein fibrils mediates inflammatory response of microglia","volume":"40","author":"Long","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib38","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1084\/jem.20182191","article-title":"Fyn kinase regulates misfolded \u03b1-synuclein uptake and NLRP3 inflammasome activation in microglia","volume":"216","author":"Panicker","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpet.2025.103735_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41531-018-0061-5","article-title":"NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson\u2019s disease","volume":"4","author":"von Herrmann","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.jpet.2025.103735_bib40","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81943","article-title":"Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice","volume":"11","author":"Szego","year":"2022","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib41","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","article-title":"Microglia clear neuron-released \u03b1-synuclein via selective autophagy and prevent neurodegeneration","volume":"11","author":"Choi","year":"2020","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.jpet.2025.103735_bib42","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1523\/JNEUROSCI.5610-12.2013","article-title":"MHCII is required for \u03b1-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration","volume":"33","author":"Harms","year":"2013","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.jpet.2025.103735_bib43","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0165-5728(00)00422-7","article-title":"Lymphocyte populations in Parkinson\u2019s disease and in rat models of parkinsonism","volume":"113","author":"Bas","year":"2001","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103735_bib45","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","article-title":"CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease","volume":"7","author":"Saunders","year":"2012","journal-title":"J Neuroimmune Pharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103735_bib46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41423-020-00530-6","article-title":"Human immunology and immunotherapy: main achievements and challenges","volume":"18","author":"Varad\u00e9","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jpet.2025.103735_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson\u2019s disease: current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12974-017-0994-3","article-title":"Peripheral immune tolerance alleviates the intracranial lipopolysaccharide injection-induced neuroinflammation and protects the dopaminergic neurons from neuroinflammation-related neurotoxicity","volume":"14","author":"Liu","year":"2017","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12031-007-0012-9","article-title":"Origins and effects of extracellular alpha-synuclein: implications in Parkinson\u2019s disease","volume":"34","author":"Lee","year":"2008","journal-title":"J Mol Neurosci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jnc.14704","article-title":"How is alpha-synuclein cleared from the cell?","volume":"150","author":"Stefanis","year":"2019","journal-title":"J Neurochem"},{"key":"10.1016\/j.jpet.2025.103735_bib51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nbd.2018.11.024","article-title":"Naturally occurring autoantibodies against \u03b1-synuclein rescues memory and motor deficits and attenuates \u03b1-synuclein pathology in mouse model of Parkinson\u2019s disease","volume":"124","author":"Huang","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-017-0187-7","article-title":"Autoimmune antibody decline in Parkinson\u2019s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies","volume":"12","author":"Brudek","year":"2017","journal-title":"Mol Neurodegener"},{"issue":"4","key":"10.1016\/j.jpet.2025.103735_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060726","article-title":"Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease","volume":"8","author":"Nagele","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-065X.2012.01128.x","article-title":"Pathogenic and physiological autoantibodies in the central nervous system","volume":"248","author":"Gold","year":"2012","journal-title":"Immunol Rev"},{"issue":"7660","key":"10.1016\/j.jpet.2025.103735_bib55","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib56","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib57","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/NEN.0b013e31829768d2","article-title":"\u03b1-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model","volume":"72","author":"Sanchez-Guajardo","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/jnc.14330","article-title":"Measurements of auto-antibodies to \u03b1-synuclein in the serum and cerebral spinal fluids of patients with Parkinson\u2019s disease","volume":"145","author":"Akhtar","year":"2018","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib59","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/jnc.14340","article-title":"What autoantibodies tell us about the pathogenesis of Parkinson\u2019s disease: an Editorial for \u201cMeasurements of auto-antibodies to \u03b1-synuclein in the serum and cerebral spinal fluids of patients with Parkinson\u2019s disease\u201d on page 489","volume":"145","author":"Bach","year":"2018","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system \u2013 associations, mechanisms and therapeutics","volume":"16","author":"Tan","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103735_bib61","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.3390\/ijms23126554","article-title":"Alpha-synuclein autoimmune decline in prodromal multiple system atrophy and Parkinson\u2019s disease","volume":"23","author":"Folke","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40120-018-0122-z","article-title":"Emerging immunotherapies for Parkinson disease","volume":"8","author":"Zella","year":"2019","journal-title":"Neurol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jpet.2025.103735_bib63","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1353-8020(11)70006-2","article-title":"Vaccination for Parkinson\u2019s disease","volume":"18","author":"Schneeberger","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jnc.14207","article-title":"Vaccination strategies in tauopathies and synucleinopathies","volume":"143","author":"Braczynski","year":"2017","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40259-024-00646-5","article-title":"Recombinant antibody fragments for immunotherapy of Parkinson\u2019s disease","volume":"38","author":"Manoutcharian","year":"2024","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.jpet.2025.103735_bib66","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1089\/scd.2010.0466","article-title":"Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans","volume":"20","author":"Ra","year":"2011","journal-title":"Stem Cells Dev"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JPD-189004","article-title":"Clinical trial highlights: targetting alpha-synuclein","volume":"9","author":"McFarthing","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib68","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib69","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrd.2017.95","article-title":"Zeroing in on neurodegenerative \u03b1-synuclein","volume":"16","author":"Kingwell","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2025.103735_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.733857","article-title":"Amyloid-\u03b2 and \u03b1-synuclein immunotherapy: from experimental studies to clinical trials","volume":"15","author":"Nimmo","year":"2021","journal-title":"Front Neurosci"},{"issue":"11","key":"10.1016\/j.jpet.2025.103735_bib74","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2023","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.jpet.2025.103735_bib75","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103735_bib76","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib77","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/biom12020168","article-title":"Passive immunization in alpha-synuclein preclinical animal models","volume":"12","author":"Folke","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jpet.2025.103735_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jpet.2025.103735_bib80","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jpet.2025.103735_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.705407","article-title":"A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s disease (PASADENA): rationale, design, and baseline data","volume":"12","author":"Pagano","year":"2021","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14712598.2023.2227378","article-title":"Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies","volume":"23","author":"Singh Gautam","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/09727531221136349","article-title":"Future of monoclonal antibody therapy in Parkinson\u2019s disease","volume":"30","author":"Kharel","year":"2023","journal-title":"Ann Neurosci"},{"key":"10.1016\/j.jpet.2025.103735_bib84","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib85","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209137","article-title":"Cinpanemab in early Parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial","volume":"102","author":"Hutchison","year":"2024","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jpet.2025.103735_bib86","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/psp4.12538","article-title":"Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain","volume":"9","author":"Kuchimanchi","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib87","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov Disord"},{"issue":"23","key":"10.1016\/j.jpet.2025.103735_bib89","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.3390\/molecules26237351","article-title":"Toward a disease-modifying therapy of alpha-synucleinopathies: new molecules and new approaches came into the limelight","volume":"26","author":"Upcott","year":"2021","journal-title":"Molecules"},{"issue":"4877","key":"10.1016\/j.jpet.2025.103735_bib90","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103735_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib92","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/jnc.14713","article-title":"Antibodies against alpha-synuclein: tools and therapies","volume":"150","author":"Vaikath","year":"2019","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-\u03b1-synuclein immunotherapy reduces \u03b1-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"10.1016\/j.jpet.2025.103735_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165964","article-title":"Bifunctional anti-non-amyloid component \u03b1-synuclein nanobodies are protective in situ","volume":"11","author":"Butler","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib95","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jmb.2007.11.096","article-title":"An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity","volume":"377","author":"Lynch","year":"2008","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib96","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40478-016-0409-1","article-title":"Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy","volume":"5","author":"Valera","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"17","key":"10.1016\/j.jpet.2025.103735_bib97","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1074\/jbc.M806559200","article-title":"Detecting morphologically distinct oligomeric forms of alpha-synuclein","volume":"284","author":"Emadi","year":"2009","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib98","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzq022","article-title":"Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm","volume":"23","author":"Kvam","year":"2010","journal-title":"Protein Eng Des Sel"},{"issue":"14","key":"10.1016\/j.jpet.2025.103735_bib99","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.jmb.2013.01.040","article-title":"Nanobodies raised against monomeric \u03b1-synuclein distinguish between fibrils at different maturation stages","volume":"425","author":"Guilliams","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jpet.2025.103735_bib100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson\u2019s disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib101","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2010.08.001","article-title":"Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies","volume":"88","author":"Gal-Tanamy","year":"2010","journal-title":"Antiviral Res"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103735_bib102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0022-1759(99)00159-3","article-title":"Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS","volume":"231","author":"Marasco","year":"1999","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jpet.2025.103735_bib103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0065-3233(08)60493-3","article-title":"Antibody binding sites","volume":"49","author":"Huston","year":"1996","journal-title":"Adv Protein Chem"},{"issue":"1\u20133","key":"10.1016\/j.jpet.2025.103735_bib104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","article-title":"Camelid immunoglobulins and nanobody technology","volume":"128","author":"Muyldermans","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103735_bib105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/CVI.00611-15","article-title":"Adenoviral expression of a bispecific VHH-based neutralizing agent that targets protective antigen provides prophylactic protection from anthrax in mice","volume":"23","author":"Moayeri","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"13","key":"10.1016\/j.jpet.2025.103735_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311022","article-title":"Are therapies that target \u03b1-synuclein effective at halting Parkinson\u2019s disease progression? A systematic review","volume":"24","author":"Rodger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103735_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104619","article-title":"Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders","volume":"134","author":"Messer","year":"2020","journal-title":"Neurobiol Dis"},{"issue":"14","key":"10.1016\/j.jpet.2025.103735_bib108","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.jmb.2013.03.031","article-title":"The mysterious C-terminal tail of alpha-synuclein: nanobody\u2019s guess","volume":"425","author":"Eliezer","year":"2013","journal-title":"J Mol Biol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103735_bib109","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3233\/JPD-130252","article-title":"Can intrabodies serve as neuroprotective therapies for Parkinson\u2019s disease? Beginning thoughts","volume":"3","author":"Bhatt","year":"2013","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"10.1016\/j.jpet.2025.103735_bib110","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.3390\/ijms24032632","article-title":"Targeting the brain with single-domain antibodies: greater potential than stated so far?","volume":"24","author":"Tsitokana","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jpet.2025.103735_bib111","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1007\/s10571-023-01404-x","article-title":"A perfused in vitro human iPSC-derived blood-brain barrier faithfully mimics transferrin receptor-mediated transcytosis of therapeutic antibodies","volume":"43","author":"Burgio","year":"2023","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib112","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib113","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/pharmaceutics14071335","article-title":"A single domain shark antibody targeting the transferrin receptor 1 delivers a TrkB agonist antibody to the brain and provides full neuroprotection in a mouse model of Parkinson\u2019s disease","volume":"14","author":"Clarke","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib114","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3233\/JPD-191787","article-title":"Downregulation of \u03b1-synuclein protein levels by an intracellular single-chain antibody","volume":"10","author":"Chen","year":"2020","journal-title":"J Parkinsons Dis"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/genes12060948","article-title":"Administration of AAV-alpha synuclein NAC antibody improves locomotor behavior in rats overexpressing alpha synuclein","volume":"12","author":"Chen","year":"2021","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib116","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ymthe.2022.11.002","article-title":"AAV-mediated neuronal expression of an scFv antibody selective for A\u03b2 oligomers protects synapses and rescues memory in Alzheimer models","volume":"31","author":"Selles","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jpet.2025.103735_bib117","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3389\/fphar.2018.01208","article-title":"Targeted intracellular delivery of antibodies: the state of the art","volume":"9","author":"Slastnikova","year":"2018","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103735_bib118","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat Neurosci"},{"issue":"4","key":"10.1016\/j.jpet.2025.103735_bib119","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40259-020-00419-w","article-title":"Applying antibodies inside cells: principles and recent advances in neurobiology, virology and oncology","volume":"34","author":"Zhang","year":"2020","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.jpet.2025.103735_bib120","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3390\/biom10121701","article-title":"Nanobodies right in the middle: intrabodies as toolbox to visualize and modulate antigens in the living cell","volume":"10","author":"Wagner","year":"2020","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.jpet.2025.103735_bib121","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2004.08.019","article-title":"A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein","volume":"10","author":"Zhou","year":"2004","journal-title":"Mol Ther"},{"issue":"6776","key":"10.1016\/j.jpet.2025.103735_bib122","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/35006074","article-title":"A Drosophila model of Parkinson\u2019s disease","volume":"404","author":"Feany","year":"2000","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jpet.2025.103735_bib123","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrn1199","article-title":"The role of alpha-synuclein in Parkinson\u2019s disease: insights from animal models","volume":"4","author":"Maries","year":"2003","journal-title":"Nat Rev Neurosci"},{"issue":"10","key":"10.1016\/j.jpet.2025.103735_bib124","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1021\/bi036281f","article-title":"Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments","volume":"43","author":"Emadi","year":"2004","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.jpet.2025.103735_bib125","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jmb.2007.02.089","article-title":"Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity","volume":"368","author":"Emadi","year":"2007","journal-title":"J Mol Biol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103735_bib126","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acn3.321","article-title":"\u03b1-Synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease","volume":"3","author":"Spencer","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005727","article-title":"Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity","volume":"4","author":"Kvam","year":"2009","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jpet.2025.103735_bib128","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/protein\/gzl036","article-title":"Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies","volume":"19","author":"Barkhordarian","year":"2006","journal-title":"Protein Eng Des Sel"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jmb.2007.02.058","article-title":"Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein","volume":"368","author":"Ellisdon","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jpet.2025.103735_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/0471143030.cb1708s23","article-title":"Isothermal titration calorimetry","author":"Vel\u00e1zquez-Campoy","year":"2004","journal-title":"Curr Protoc Cell Biol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103735_bib131","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jmb.2010.07.001","article-title":"Structure and properties of a complex of \u03b1-synuclein and a single-domain camelid antibody","volume":"402","author":"De Genst","year":"2010","journal-title":"J Mol Biol"},{"issue":"15","key":"10.1016\/j.jpet.2025.103735_bib132","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1111\/febs.16376","article-title":"Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity","volume":"289","author":"Hmila","year":"2022","journal-title":"FEBS J"},{"issue":"24","key":"10.1016\/j.jpet.2025.103735_bib133","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1073\/pnas.0610659104","article-title":"Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass","volume":"104","author":"Knowles","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib134","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","article-title":"Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective","volume":"19","author":"Knecht","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.jpet.2025.103735_bib135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14802\/jmd.15059","article-title":"Mechanism of anti-\u03b1-synuclein immunotherapy","volume":"9","author":"Lee","year":"2016","journal-title":"J Mov Disord"},{"key":"10.1016\/j.jpet.2025.103735_bib136","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/bs.irn.2019.06.014","article-title":"New therapeutic approaches to target alpha-synuclein in Parkinson\u2019s disease: the role of immunotherapy","volume":"146","author":"Fern\u00e1ndez-Valle","year":"2019","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103735_bib137","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/biom11081131","article-title":"Transportation of single-domain antibodies through the blood-brain barrier","volume":"11","author":"Ruiz-L\u00f3pez","year":"2021","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.jpet.2025.103735_bib138","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"Pt B","key":"10.1016\/j.jpet.2025.103735_bib139","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103735_bib140","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s13311-020-00853-2","article-title":"Immunotherapies for aging-related neurodegenerative diseases-emerging perspectives and new targets","volume":"17","author":"Kwon","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.jpet.2025.103735_bib141","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/13543784.2020.1771693","article-title":"Immunization therapies for Parkinson\u2019s disease: state of the art and considerations for future clinical trials","volume":"29","author":"Antonini","year":"2020","journal-title":"Expert Opin Investig Drugs"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:15:46Z","timestamp":1764058546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":137,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0022356525402481"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103735","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling synucleinopathies: Recent breakthroughs in Parkinson\u2019s disease therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103735"}}